References
- Centers for Disease Control. National Nosocomial Infections Surveillance System, http://www.cdc.gov/ncidod/hip/Aresist/mrsa.htm#5, Accessed on 25 November, 2003
- Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36: 281–5
- Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003; 36: 1157–61
- Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trends in the treatment of orthopedic prosthetic infections. J Antimicrob Chemother 2004; 53: 127–9
- Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53: 928–35
- Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493–501
- Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674–80
- Tam, VH, Jumbe, NL, Briceland, LL, Miller, MH. A comparative study of vancomycin (VAN) and β-lactams in the treatment of staphylococcal bacteremia in hemodiaslysis (HD) patients. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26–29, 1999; San Francisco, CA. Abstract number: 1095.
- Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–402
- Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549–55
- Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47: 3960–3
- Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004; 48: 1007–11
- Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669–74
- Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530–2
- Tsuji, BT, Rybak, MJ. Short course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Presented at the 44th ICAAC. 30 Oct–2 Nov, 2004; Washington, DC. Abstract number: A-1171.
- Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33: 689–92
- Oleson FB, Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44: 2948–53
- Echevarria K, Datta P, Cadena J, Lewis JS. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55: 599–600